Latest News for: taiho
Edit
The Galveston Daily News
28 Jan 2026
Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer
The Galveston Daily News
28 Jan 2026
Edit
Hastings Tribune
20 Jan 2026
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
Hastings Tribune
20 Jan 2026
Edit
The Pilot News
09 Dec 2025
Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at ...
The Pilot News
09 Dec 2025
Edit
Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
PR Newswire 08 Dec 2025
About Taiho Oncology, Inc. The mission of Taiho Oncology, Inc ... Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... SOURCE Taiho Oncology.
Edit
Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible ...
Business Wire 03 Dec 2025
Edit
Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocarcinoma1
Pharmiweb 03 Dec 2025
Edit
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information (NEC Corporation)
Public Technologies 28 Nov 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 128016808) .
Edit
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
JCN Newswire 28 Nov 2025
TOKYO, Nov 28, 2025 - (JCN Newswire) - The Japanese Foundation for Cancer Research (JFCR), NEC Corporation (NEC), and Taiho Pharmaceutical Co., Ltd ... About Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd.
Edit
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PR Newswire 20 Nov 2025
20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc ... Taiho Pharmaceutical ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology.
Edit
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (Cullinan Therapeutics Inc)
Public Technologies 20 Nov 2025
Edit
Biltmore Beacon
14 Nov 2025
Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of ...
Biltmore Beacon
14 Nov 2025
Six oral presentations will detail new data on the ...
- 1
